Compositions and methods for treating hyperproliferative skin disorders
Compositions and methods are provided that are effective in treating skin hyperproliferative disorders. These include a topical pharmaceutical preparation that includes a compound that has two or more of a SRC-kinase inhibiting activity, a tubulin polymerization inhibiting activity, an activity that arrests the cell cycle at G2/M, and an activity that induces apoptosis. The compound KX01 is provided as an example of such a compound. The topical pharmaceutical preparation further includes a vitamin D derivative or a retinoid, where the combination provides a synergistic effect. Use of the topical pharmaceutical preparation can be combined with exposure to blue, UVA, or UVB light, which provides a synergistic effect.
1. A method of treating actinic keratosis in a subject in need thereof, the method comprising:
topically applying, to an area of the subject's skin affected by actinic keratosis, an effective amount of a composition comprising calcipotriol and KX01, which has the following structure:
and
wherein the calcipotriol and the KX01 are present in synergistic concentrations that are therapeutically effective.
2. The method of claim 1 , wherein the composition is topically applied at a frequency of once per week to four times per day.
3. The method of claim 1 , wherein the composition further comprises a retinoid.
4. The method of claim 3 , wherein the retinoid has at least one activity selected from the group consisting of induction of keratinocytes proliferation, modulation of epidermal differentiation, stimulation of extracellular matrix production, and alteration of sebocyte differentiation.
5. A method of treating psoriasis in a subject in need thereof, the method comprising:
topically applying, to an area of the subject's skin affected by psoriasis, an effective amount of a composition comprising calcipotriol and KX01, which has the following structure:
and
wherein the calcipotriol and the KX01 are present in synergistic concentrations that are therapeutically effective.
6. The method of claim 5 , wherein the composition is topically applied at a frequency of once per week to four times per day.
7. The method of claim 5 , wherein the composition further comprises a retinoid.
8. The method of claim 7 , wherein the retinoid has at least one activity selected from the group consisting of induction of keratinocytes proliferation, modulation of epidermal differentiation, stimulation of extracellular matrix production, and alteration of sebocyte differentiation.